tbuckley/cabot-search huggingface dataset:
Identification of therapy options for rare and resistant gastrointestinal stromal tumors (GIST).
Authors: Rebecca Feldman, Sandeep K. Reddy, Zoran Gatalica, Michael J. Pishvaian
Journal: Journal of Clinical Oncology (2015)

10539 Background: GISTs are predominantly defined by KIT/PDGFRA mutations which are targetable with a range of kinase inhibitors, however the majority become TKI-resistant (TKI-R). Double (KIT/PDGFRA) wildtype (D-WT) GISTs represent a rare subset of GIST patients in need of treatment options. We investigated a commercial database of theranostic biomarkers for the identification of novel therapy options for GIST. Methods: 217 GIST cases were evaluated for D-WT and TKI-R. A multiplatform approach of biomarker testing was used and included a combination of sequencing (NGS, Sanger), protein expression (IHC) and gene amplification (ISH). Results: D-WT (n = 15) and TKI-R (n = 23) (including 7 with resistance mutations in the absence of a primary, activating KIT mutation and 4 PDGFRA D842V) were studied for additional targetable alterations. IHC and ISH tests revealed no overexpression or amplification in cMET, EGFR, or HER2. PTEN was intact (positive expression) in the majority of GISTs (92.9% (13/14) D-WT; 100% (19/19) TKI-R). Mutational screening revealed variants in 6/47 genes (excluding cKIT and PDGFRA), most of which are potentially targetable with therapies currently available, or in clinical trials: PIK3CA, ABL, cMET, JAK3, RB1, and VHL. ABL and JAK3 mutations were exclusively found in the TKI-R subgroup. PD-1 positive tumor infiltrating lymphocytes were found in 33% (1/3 D-WT) and 60% (3/5 TKI-R), while PD-L1 tumor expression was found in 67% (2/3 D-WT) and 40% (2/5 TKI-R). Although chemotherapy has historically elicited poor responses in GIST (non-selected patient trials), we observed a high frequency of low expression of predictive markers for gemcitabine (RRM1) and paclitaxel (TUBB3) (77%, 90%; 57%, 73% for D-WT and TKI-R, respectively) and high frequency of TOPO1 overexpression for irinotecan (57%, 32% in D-WT and TKI-R, respectively) which were recently shown to be cytotoxic in TKI-R GIST cell lines (Boichuk, 2014). Conclusions: A multiplatform approach of theranostic biomarkers identified non-cKIT/PDGFRA therapy options for rare and resistant GIST. Opportunities for investigating new targetable agents and potentially re-visiting cytotoxics with biomarker guidance in these subpopulations are warranted.
SAT-152-Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation
Authors: Giacomo Zaccherini, Maurizio Baldassarre, Michele Bartoletti, Sonia Berardi, Mariarosa Tame, Lucia Napoli, Antonio Siniscalchi, Angela Fabbri, Lorenzo Marconi, Agnese Antognoli, Giulia Iannone, Marco Domenicali, Pierluigi Viale, Franco Trevisani, Mauro Bernardi, Paolo Caraceni
Journal: Journal of Hepatology (2019)
TCTAP C-014 Myocardial Infarction with Non-Obstructive Coronary Arteries: A Shifting Paradigm
Authors: Hendy Bhaskara Perdana Putra, Putri Dariyanti Wijaya, Bestya Presidiana, Ragil Nur Rosyadi, Benny Jovie
Journal: Journal of the American College of Cardiology (2019)
Facility-Level Variation in Stress Test Utilization in Veterans With Ischemic Heart Disease
Authors: Nishant R. Shah, Sarah T. Ahmed, David E. Winchester, David J. Ramsey, Julia M. Akeroyd, Wen-Chih Wu, Stephen W. Waldo, Richard S. Schofield, Christie M. Ballantyne, Laura A. Petersen, Salim S. Virani
Journal: JACC. Cardiovascular imaging (2019)
Improving CAR T cell immunotherapy–mediated remissions for pediatric leukemia
Authors: David M. Barrett
Journal: Journal of Clinical Investigation (2019)

Chimeric antigen receptor (CAR) T cells are an effective therapy for relapsed or refractory pediatric B cell leukemia. Analysis of the starting material, the T cells collected from the patient prior to CAR manufacture, reveals possible biomarkers of cells destined to perform poorly in patients. Long-term follow-up shows that long periods of B cell aplasia, a marker of in vivo CAR activity, are associated with longer remission but also a higher chance of antigen-negative relapse. The role of transplantation as consolidative therapy is unclear in this nonrandomized data, but clearly warrants further study.
TCTAP A-134 Biodegradable Polymer vs. Durable Polymer Drug-eluting Stents in Patients with Acute Myocardial Infarction Patients
Authors: Ahmed Mashaly, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Ja Kyeong Byun, Kareem Abdelshafi, Yoonjee Park, Dong Oh Kang, Won Young Jang, Woohyeun Kim, Eun Jin Park, Jin Oh Na, Cheolung Choi, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo
Journal: Journal of the American College of Cardiology (2019)
Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)
Authors: Neil P. Shah, Jose Valentín García Gutiérrez, Antonio Jiménez-Velasco, Sarah M Larson, Susanne Saussele, Delphine Rea, François-Xavier Mahon, Moshe Levy, María Teresa Gómez-Casares, Fabrizio Pane, Franck-Emmanuel Nicolini, Michael J. Mauro, Oumar Sy, Patricia Martin-Regueira, Jeffrey H. Lipton
Journal: Blood (2017)
FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection
Authors: Joaquin Cabezas, Inmaculada Fernández Vázquez, Susana Llerena, Jose A. Carrión, Adolfo Gallego Moya, Sabela Lens, José Luis Calleja Panero, Juan Manuel Pascasio, M Prieto, Francisco Gea, Jose Maria Moreno-Planas, Isabel Carmona, Diego Rincón, Esther Badia-Aranda, Moises Diago, Rosa Morillas, Juan Turnés, Juan Arenas, Ana Arencibia, Javier Crespo
Journal: Journal of Hepatology (2019)
Intestinal Microbiota in Early Life and Its Implications on Childhood Health
Authors: Lu Zhuang, Haihua Chen, Sheng Zhang, Jiahui Zhuang, Qiuping Li, Zhichun Feng
Journal: Genomics Proteomics & Bioinformatics (2019)

Abstract Trillions of microbes reside in the human body and participate in multiple physiological and pathophysiological processes that affect host health throughout the life cycle. The microbiome is hallmarked by distinctive compositional and functional features across different life periods. Accumulating evidence has shown that microbes residing in the human body may play fundamental roles in infant development and the maturation of the immune system. Gut microbes are thought to be essential for the facilitation of infantile and childhood development and immunity by assisting in breaking down food substances to liberate nutrients, protecting against pathogens, stimulating or modulating the immune system, and exerting control over the hypothalamic–pituitary–adrenal axis. This review aims to summarize the current understanding of the colonization and development of the gut microbiota in early life, highlighting the recent findings regarding the role of intestinal microbes in pediatric diseases. Furthermore, we also discuss the microbiota-mediated therapeutics that can reconfigure bacterial communities to treat dysbiosis.
Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM + LoDEX) in the MM-003 trial.
Authors: Katja Weisel, Philippe Moreau, Craig J Gibson, Kevin W. Song, Owain Saunders, Lars Axel Sternas, Kevin Hong, Mohamed H. Zaki, Meletios A. Dimopoulos
Journal: Journal of Clinical Oncology (2015)

8593 Background: RRMM patients (pts) previously exposed to bortezomib (BORT) and lenalidomide (LEN) have short overall survival (OS). The phase 3 MM-003 trial (NCT01311687) demonstrated significantly longer OS in RRMM pts treated with POM + LoDEX vs HiDEX (HR, 0.74 [95% CI, 0.56-0.97], P = .0285). This post hoc analysis investigated OS based on the response status of pts at different cycles. Methods: Landmark analyses at the start of cycles (C) 3, 5, and 7 were performed using Kaplan-Meier methods and unadjusted Cox regression models. Time-dependent survival analyses captured response status over time. For both approaches, survival of ptswith stable disease (SD) was compared to that of pts with progressive disease (PD) or overall response (OR; ≥ partial response). Results: At C3, 38.4% of pts (116/302) randomized to POM + LoDEX attained SD, 14.6% PD, and 19.2% OR; 28% had no response data, most due to early discontinuation. The median OS from randomization by response status at C3 was 15.3 mos for SD, 6.3 for PD, and 17.5 for OR. The difference in OS at C3 between pts with PD or SD was significant (P < .001); that between pts with OR or SD was not (P = .32). A similar pattern was observed at C5 and C7. The time-dependent survival model showed a lower risk of death for pts with SD or OR vs PD (HR, 0.27 [95% CI, 0.17-0.44] and HR, 0.06 [95% CI, 0.02-0.16], respectively). For the HiDEX arm, small pt numbers per group (due to the lower response rate, 2:1 randomization, and shorter OS vs POM + LoDEX) made interpretation challenging. Conclusions: In the POM + LoDEX group, pts with SD at C3, C5, and C7 had OS comparable to pts who achieved a response by those times. Pts with either SD or OR had a longer OS than those with PD at the same time points. Clinical trial information: NCT01311687. Beginning of C POM + LoDEX (N = 302) SD PD OR C3 n 116 44 58 Median OS, mo 15.3 6.3 17.5 HR vs SD (95% CI) - 3.83 (2.39-6.14) 0.75 (0.43-1.31) P value vs SD - < .0001 .320 C5 N 57 31 56 Median OS, mo 16.6 11.0 18.0 HR vs SD (95% CI) - 2.81 (1.38-5.71) 0.74 (0.33-1.66) P value vs SD - .004 .462 C7 n 40 18 47 Median OS, mo Not reached 16.4 18.0 HR vs SD (95% CI) - 2.66 (0.89-7.94) 0.90 (0.3-2.67) P value vs SD - .080 .843
SAT-472-Massive sequencing of circulating DNA as a potential tool for diagnosis and follow-up in patients with hepatocellular carcinoma
Authors: Monica Higuera, Elena Vargas-Accarino, María Eugenia Soria, Josep Gregori, Maria Torrens, María Teresa Salcedo, Itxarone Bilbao, Francisco Rodríguez-Frías, Josep Quer, Beatriz Minguez
Journal: Journal of Hepatology (2019)
Patient choice in elective care increased emergency readmissions
Authors: Nigel Hawkes
Journal: BMJ (2019)

Introducing competition into the NHS in England to try to drive up quality had the perverse effect of lowering it for some elective procedures, a team of economists from Surrey and York universities has found.

In a paper presented this week at the Royal Economic Society’s conference in Warwick, the authors said that emergency readmissions after hip and knee replacements rose after patient choice was introduced between 2006 and 2008.1 Greater numbers of emergency readmissions imply a lower quality of care.

Emergency readmissions after hip replacements rose by 8.5% and after knee replacements by 7.7%, …
SAT-485-European cliolangiocarcinoma (EU-CCA) registry: An initiative to broaden awareness on the second most common primary liver cancer
Authors: Alvaro Santos-Laso, Angela Lamarca, Adelaida La Casta, Chiara Braconi, Jorge Adeva, Matthias Evert, Alejandro Forner, Rocio IR Macias, Marek Krawczyk, Laura Izquierdo-Sánchez, Vincenzo Cardinale, Guido Carpino, Domenico Alvaro, Juan Valle, Jesús María Banales
Journal: Journal of Hepatology (2019)
FRI-053-Overlap of primary biliary cholangitis and autoimmune hepatitis. Natural history and prognosis in a large cohort of patients from Spain
Authors: Anna Reig, Laura Patricia Llovet, Manuel Romero Gomez, Mercedes Vergara Gómez, Agustin Albillos, Federico Sáez-Royuela, Emilio Fabrega, Javier Salmerón, Diana Horta, Raul J. Andrade, Adolfo Gallego Moya, Elena Gómez Domínguez, Eva Fernandez Bonilla, Margarita Sala, Carlos Ferre, José Antonio Carrión, Andrés Castano-Garcia, Isabel Conde, Manuel Hernández Guerra, Jesús M. González-Santiago, Nadia Chahri, Pamela Estevez, Conrado Manuel Fernandez Rodriguez, Moises Diago, Albert Parés
Journal: Journal of Hepatology (2019)
TCTAP A-027 The Benefits of Cardiac Rehabilitation on Clinical Parameters in Patients with Acute Coronary Syndrome
Authors: Gwang-Seok Yoon, Seong-Huan Choi, Jin-Hee Park, Yong-Soo Baek, Sung Woo Kwon, Sang-Don Park, Seong-Ill Woo, Dae-Hyeok Kim, Jun Kwan
Journal: Journal of the American College of Cardiology (2019)
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a phase 1 clinic.
Authors: Goldy George, Eucharia Chiege Iwuanyanwu, Karen O Anderson, Sarina Anne Piha-Paul, Jennifer J. Wheler, Ralph Zinner, Aung Naing, Apostolia Maria Tsimberidou, Filip Janku, Vivek Subbiah, Charles S. Cleeland, Tito R. Mendoza, David S. Hong
Journal: Journal of Clinical Oncology (2015)

9624 Background: Limited data exist about sleep quality (SQ) in patients (pts) on phase 1 clinical trials. Poor SQ is often not captured as an adverse event (AE) and its association with fatigue, one of the most frequently reported AEs, is not documented routinely. Here, we describe SQ and the relation between SQ and fatigue, symptoms, and mood in pts in the MD Anderson phase 1 clinical trials clinic. Methods: Sleep, fatigue, symptom severity/interference and mood were assessed using the validated Pittsburgh Sleep Quality Index (PSQI), Brief Fatigue Inventory, MD Anderson Symptom Inventory, and Profile of Mood States, respectively; ECOG was from medical records. Statistics included multivariable regression models. Results: The sample (N = 262) was 52% female, 80% ECOG 0-1, mean age 58.4 ± 0.7y. The % of “poor” sleepers (global PSQI score > 5) was 64%. In contrast, pts’ subjective self-assessment of SQ was: 27% as “bad” or “fairly bad”, 59% as “fairly good” and 14% as “very good”. Among pts, 28% took medicines for sleep; 15% slept < 6 hours at night; 20% had sleep latency > 30 minutes for ≥ 3 nights per week; and 42% reported poor sleep efficiency ( < 85% time in bed spent sleeping). The % of pts reporting fatigue were 35% as “severe”, 14% as “moderate”, 39% as “mild”, and 12% “none”. In an adjusted multivariable regression model, poor overall SQ was associated with greater fatigue (P < 0.001). Interestingly, SQ (PSQI) sub-components associated with greater fatigue were sleep disturbance (OR = 2.6, 95% CI = 1.3, 5.1, P < 0.007) and daytime dysfunction (OR = 4.1, 95% CI = 2.3, 7.6, P < 0.001), but sleep latency, and sleep efficiency were not related to fatigue. Poor overall SQ also was associated with higher symptom severity (Pearson’s r = 0.6, P < 0.001), mood disturbance (Pearson’s r = 0.5, P< 0.001), and greater fatigue- (Pearson’s r = 0.4, P < 0.001) and symptom-related interference (Pearson’s r = 0.5, P < 0.001) with activity, walking ability, relationships with others, and enjoyment of life. Conclusions: Poor SQ is a significant problem (64% pts) and associated with greater fatigue, symptom severity, symptom interference, and greater mood disturbance. Deciphering SQ should be routine practice in phase 1 clinical assessments.
Final overall survival (OS) analysis of a multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-RT) without elective nodal irradiation with chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) in patients with stage III non-small cell lung cancer (NSCLC).
Authors: Hidehito Horinouchi, Ikuo Sekine, Minako Sumi, Toshinori Soejima, Miyako Satouchi, Hisayasu Nagakura, Hiroshi Isobe, Noriaki Nishiyama, Masao Harada, Naoki Ishizuka, Tomohide Tamura, Yuichiro Ohe
Journal: Journal of Clinical Oncology (2015)

7526 Background: We previously reported the adverse events and objective responses in a multicenter phase II study of high-dose chemoradiotherapy. This is a final analysis of the pattern of recurrences, progression free survival (PFS) and OS. Methods: Patients with stage III NSCLC were eligible if they met the following key criteria: age between 20 and 74 years, PS 0-1 and V20 ≤ 30%. Participants received 3-4 cycles of CDDP (80 mg/m2 day 1) and VNR (20 mg/m2days 1 and 8) every 4 weeks. The 3D-RT was administered at a total dose of 72 Gy divided into 36 fractions from day 1 chemotherapy. The primary endpoint was the 2-year survival rate and the planned sample size was 60 to reject the rate of 45% under the expectation of 65% with a power of 90% and an alpha error of 5%. Results: Thirty-one patients were enrolled between 2009 and 2011. The median follow-up time (range) was 51.4 (28.8-65.6) months at the point of data cut-off. This trial was terminated early due to the slow accrual and appearance of grade 5 pulmonary toxicities in 2 patients. There were 25 men and 6 women with a median (range) age of 59 (32-72) years. Of the 25, 23 had adenocarcinoma and 21 had stage IIIA disease. The median (range) V20value was 20 (9-30). Among the 20 patients showing disease progression, in-field failures were observed in 5 (25%) patients as the first relapse and a further 4 patients (9 [45%] patients in total) during the follow-up period. The 2-, 3-, and 5-year PFS rates (95% CI) were 44.9% (27.1-61.2), 34.6% (18.5-51.2), and 34.6% (18.5-51.2), respectively. The 2-, 3-, and 5-year OS rates (95% CI) were 64.5% (45.2-78.5), 51.2% (32.6-67.1), and 43.8% (25.8-60.5), respectively. The median PFS and median survival time were 17.1 months and 41.2 months, respectively. Conclusions: The higher TRT dose associated both with an unacceptable incidence of pulmonary toxicities and with relatively better long-term survival. Development of a better strategy is warranted to obtain both a better outcome and tolerable pulmonary toxicities. Clinical trial information: UMIN000001743.
Abstract 15534: Interpreting HCM Genetic Testing in the Age of the Exome
Authors: Jamie D Kapplinger, Martijn Bos, Thomas E Callis, Michael J Ackerman
Journal: Circulation (2013)

Introduction: Recent publications from the 1000 genomes project (1kG) and the NHLBI Exome Sequencing project (ESP) have exposed the presence of rare (minor allele frequency (MAF) < 0.5%) non-synony...
Abstract 10654: Treatment Effect of Corticosteroids Therapy Incardiac Sarcoidosis as Measured by Cardiac PET Imaging
Authors: Muhammad Khan, Shiva Mudaliar, David Collins, Santabhanu Chakrabarti, Tawimas Shaipanich, Andrew Ignaszewski, Mustafa Toma
Journal: Circulation (2018)

Introduction: The prevalence of cardiac sarcoidosis (CS) has increased in the past 10 years due to increased awareness and improved imaging modalities. PET scans are increasingly used to diagnose a...
Dowling Munro: dermatologist who specialised in research into topical steroids
Authors: Matt Limb
Journal: BMJ (2019)

Dowling Munro was a consultant dermatologist who did pioneering research into topical steroids. He studied the side effects of these drugs as new and more powerful ones emerged from the 1950s and 1970s and was also influential in the classification of steroids into four classes of potency.

His analysis of the complications of steroid treatment was “in the forefront of dermatology at that time,” says Anthony du Vivier, who worked with Munro at St Bartholomew’s Hospital in London. Topical steroids are used to treat numerous inflammatory skin conditions, including eczema and psoriasis. Their anti-inflammatory effects are elicited by reducing the skin’s immune response. Du Vivier, who is a consultant dermatologist at King’s College Hospital, London, says, “Topical steroids completely transformed dermatology because, before them, treating disorders such as eczema was a nightmare. But these drugs have potential side effects. One of the areas Munro worked in was the absorption of these steroids through the skin, demonstrating that they could result in adrenal suppression.

“This was to become of particular importance when clobetasol propionate (Dermovate) was launched in 1974, …
Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children
Authors: Maribeth R. Nicholson, Paul D. Mitchell, Erin Alexander, Sonia Ballal, Mark Bartlett, Penny Becker, Zev Davidovics, Michael Docktor, Michael Dole, Grace Felix, Jonathan Gisser, Suchitra K. Hourigan, M. Kyle Jensen, Jess L. Kaplan, Judith Kelsen, Melissa Kennedy, Sahil Khanna, Elizabeth Knackstedt, McKenzie Leier, Jeffery Lewis, Ashley Lodarek, Sonia Michail, Maria Oliva-Hemker, Tiffany Patton, Karen Queliza, George H. Russell, Namita Singh, Aliza Solomon, David L. Suskind, Steven Werlin, Richard Kellermayer, Stacy A. Kahn
Journal: Clinical Gastroenterology and Hepatology (2019)
Temporal trends in health status among adults in the Childhood Cancer Survivor Study (CCSS).
Authors: Kirsten K. Ness, Melissa M. Hudson, Kendra E Jones, Wendy M. Leisenring, Marilyn Stovall, Daniel M. Green, Joseph Philip Neglia, Tara O. Henderson, Jacqueline N. Casillas, Jennifer Ford, Karen Elizabeth Effinger, Kevin C. Oeffinger, Gregory T. Armstrong, Leslie L. Robison, Paul C. Nathan
Journal: Journal of Clinical Oncology (2015)

10020 Background: The impact of temporal changes in childhood cancer therapy on long-term health status has not been evaluated. With expansion of CCSS, information about health status is available for 5+ year survivors diagnosed from 1970-1999. Methods: We estimated prevalence of poor general and mental health, functional impairment, activity limitation and cancer-related anxiety and pain at baseline evaluation among 15,830 survivors of childhood cancer. Outcomes were compared among treatment decades using log-binomial regression to calculate relative risk (RR) and 95% confidence interval (CI), adjusted for age, sex, race and diagnosis. Results: Proportions of survivors treated with radiation and amputation decreased; proportions treated with anthracyclines or alkylating agents increased over time. Survivors diagnosed more recently were more likely to report poor general health, pain and anxiety, and less likely to report functional impairment. Diagnoses with large increases (p < 0.001) in prevalence of adverse outcomes from 1970-79 to 1990-99 were leukemia (9.8 to 12.6% poor general health), bone tumor (23.2 to 30.7% pain) and Hodgkin lymphoma (15.7 to 19.2% anxiety). CNS tumor survivors had the largest decrease in functional impairment prevalence (37.7 to 19.7%). Conclusions: While the proportion of childhood cancer survivors reporting functional impairment in the most recent era decreased, particularly among CNS tumor survivors, proportions reporting poor general health, pain and anxiety increased slightly from 1970 to 1999. 1970-79 1980-89 1990-99 Median (Range) Diagnosis age (years) 8 (0-21) 11 (0-21) 10 (0-21) Age at evaluation 28 (18-48) 26 (18-48) 26 (18-42) % Male 52.4 53.4 50.6 White 89.0 83.9 76.2 Cranial radiation 33.1 24.4 12.4 Chest radiation 24.2 20.0 9.9 Amputation 5.4 4.5 1.7 Alkylating agent 27.4 59.9 58.4 Anthracycline 30.7 51.4 59.3 Mean dose (mg/m2) 335 ± 284 271 ± 144 214 ± 118 RR (95% CI) Poor general health 1.0 1.1 (1.0-1.2) 1.2 (1.1-1.3) Functional impairment 1.0 (0.9-1.1) 0.8 (0.7-0.9) Activity limitation 0.9 (0.8-1.0) 0.9 (0.8-1.0) Poor mental health 1.0 (0.9-1.1) 1.0 (0.9-1.1) Pain 1.1 (1.0-1.2) 1.2 (1.1-1.4) Anxiety 1.1 (1.0-1.3) 1.2 (1.1-1.3) *p-values for trend < 0.001.
Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States
Authors: Eytan M. Stein, Jipan Xie, Emilie Duchesneau, Subrata Bhattacharyya, Briana Ndife, Gaetano Bonifacio, George J Joseph
Journal: Blood (2017)
Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States
Authors: Nina N. Sanford, David J. Sher, Chul Ahn, Ayal A. Aizer, Brandon A. Mahal
Journal: JAMA Oncology (2019)

This cross-sectional study analyzes the proportion of patients with cancer and cancer survivors who use complementary and alternative medicine (CAM) without disclosing this information to their physicians.